secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001104659-24-000584
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Therapeutics appoints Christine Borowski, Ph.D., to board of directors effective Jan 1, 2024
--------------------------------------------------------------------------------

- Appointed Dr. Christine Borowski as Class II director, effective Jan 1, 2024, for term until 2026 annual meeting.
- Dr. Borowski is Vice President at Access Bio and was appointed per prior agreement from Nov 2023 private placement.
- Received option to purchase 40,000 shares at $2.33/share, vesting annually over 3 years.
- Will receive standard annual cash retainer of $40,000, payable quarterly, plus annual option awards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/0001104659-24-000584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924000584/tm2333851d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-000584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer